EGFR and intestinal cancer: Finally, our findings highlight the efficacy of using organoid models to recapitulate patient tumor drug sensitivities, revealing the potential of using organoids as a translational model.27-29 Tumor organoids obtained from a BRAF-V600E-driven mouse model of intestinal cancer demonstrated that combined treatment with BRAF and EGFR inhibition and FU is more effective than either modality alone, supporting a role for combined targeted and chemotherapy for MSS-stable, BRAF-V600E-mutant CRC.